Equities research analysts forecast that Phreesia, Inc. (NYSE:PHR) will report $48.26 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Phreesia’s earnings, with estimates ranging from $47.01 million to $49.30 million. Phreesia reported sales of $38.46 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 25.5%. The business is expected to announce its next earnings results on Tuesday, December 14th.
On average, analysts expect that Phreesia will report full-year sales of $197.84 million for the current fiscal year, with estimates ranging from $197.23 million to $198.40 million. For the next year, analysts anticipate that the business will report sales of $237.85 million, with estimates ranging from $223.80 million to $244.50 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Phreesia.
Phreesia (NYSE:PHR) last released its earnings results on Tuesday, August 31st. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.26). Phreesia had a negative return on equity of 13.18% and a negative net margin of 27.94%. The company had revenue of $51.01 million during the quarter, compared to analysts’ expectations of $47.22 million. During the same period in the prior year, the company posted ($0.17) earnings per share. The company’s revenue was up 45.7% on a year-over-year basis.
Shares of NYSE PHR traded up $0.61 during trading on Friday, reaching $69.40. The company had a trading volume of 15,211 shares, compared to its average volume of 440,804. Phreesia has a 12-month low of $27.79 and a 12-month high of $81.59. The stock has a market cap of $3.53 billion, a PE ratio of -63.99 and a beta of 1.21. The business’s 50-day moving average is $67.33 and its 200 day moving average is $58.48. The company has a quick ratio of 8.56, a current ratio of 8.56 and a debt-to-equity ratio of 0.01.
In related news, Director Edward L. Cahill sold 5,000 shares of Phreesia stock in a transaction that occurred on Thursday, June 24th. The stock was sold at an average price of $60.03, for a total transaction of $300,150.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Evan Roberts sold 21,091 shares of Phreesia stock in a transaction that occurred on Thursday, June 24th. The shares were sold at an average price of $60.05, for a total value of $1,266,514.55. The disclosure for this sale can be found here. Insiders sold 242,589 shares of company stock worth $16,500,457 over the last three months. Insiders own 5.60% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. Voloridge Investment Management LLC increased its stake in Phreesia by 45.0% in the 1st quarter. Voloridge Investment Management LLC now owns 137,871 shares of the company’s stock worth $7,183,000 after acquiring an additional 42,760 shares during the last quarter. Quadrature Capital Ltd increased its stake in Phreesia by 166.9% in the 1st quarter. Quadrature Capital Ltd now owns 22,762 shares of the company’s stock worth $1,186,000 after acquiring an additional 14,233 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Phreesia by 33.4% in the 2nd quarter. Kornitzer Capital Management Inc. KS now owns 374,424 shares of the company’s stock worth $22,952,000 after acquiring an additional 93,850 shares during the last quarter. Peregrine Capital Management LLC increased its stake in Phreesia by 4.5% in the 2nd quarter. Peregrine Capital Management LLC now owns 252,788 shares of the company’s stock worth $15,496,000 after acquiring an additional 10,842 shares during the last quarter. Finally, State of New Jersey Common Pension Fund D bought a new stake in Phreesia in the 1st quarter worth approximately $1,604,000. 93.90% of the stock is currently owned by institutional investors.
Phreesia Company Profile
Phreesia, Inc is a healthcare software company, which engages in the provision of patient check-in solutions for medical practices. The firm offers appointments, clinical support, integration, registration, patient activation, analytics and reports, revenue cycle, patient surveys, and privacy and security products.
Featured Article: Initial Coin Offerings entail a high degree of risk
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.